An FDA Committee Just Voted in Favor of Peptides—Despite the Agency's Opposition

An FDA advisory committee voted to recommend two peptides (BP-157 and KPV) for inclusion on the 503A bulks list, allowing compounding pharmacies to dispense them, overruling FDA staff opposition and bypassing the standard drug approval process. The decision follows a 2023 FDA ban on these substances and reflects pressure from telehealth companies and patient advocates citing grey-market alternatives as a safety concern.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.